Summary
Oral mucositis as a consequence of cytotoxic therapy is a major cause of morbidity in cancer patients. Cancer therapy-induced tissue damage leading to mucositis can occur through either direct or indirect stomatotoxicity. Once mucositis has occurred, treatment consists of measures to palliate symptoms. The prevention of cancer therapy-induced oral mucositis is less standardised. Numerous drugs have been used as prophylactic agents to prevent chemo- and radiotherapy-induced mucositis. Controlled trials have shown some degree of prophylactic efficacy for sucralfate, chlorhexidine and benzydamine. Positive but non-placebo-controlled trials requiring more study have been conducted with dinoprostone (prostaglandin E2), silver nitrate, ß-carotene, pentoxifylline and lozenges containing polymixin B, tobramycin and amphotericin B. Current studies have shown a lack of efficacy with allopurinol and granulocyte colony-stimulating factor (G-CSF). Nonpharmacological methods such as oral cryotherapy and helium-neon laser treatments have shown some promise. At the present time no agent has been shown to be uniformly efficacious and can be accepted as standard therapy. Additional studies combining several agents or incorporating nonpharmacological manoeuvres for mucositis prevention are needed.
Similar content being viewed by others
References
Ahmann FR, Garewal H, Greenberg B. Phase II trial of high-dose continuous infusion 5-fluorouracil with allopurinol modulation in colon cancer. Oncology 43: 83–85, 1986
Bianco JA, Appelbaum FR, Nemunaitis J, Almgren J, Andrews F, et al. Phase I–II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood 78: 1205–1211, 1991
Bronchud MH, Howell A, Crowther D, Hopwood P, Souza L, et al. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. British Journal of Cancer 60: 121–125, 1989
Clark PI, Sievin ML. Allopurinol mouthwashes and 5-fluorouracil induced oral toxicity. European Journal of Surgical Oncology 11: 267–268, 1985
Cohen MM, Clark L. Preventing acetylsalicyclic acid damage to human gastric mucosa by use of prostaglandin E2. Canadian Journal of Surgery 26: 116–122, 1983
Dorr W, Kummermehr J, Pfeifer H. Chemical stimulation of mouse tongue mucosa: effects on turnover rate and radiation response, Annual Report 1986, Experimental Tumour Therapy GSF, Neuherberg, 1987
Dvorkin SB, Cernookij GP. Conservative treatment of trophic skin ulcers with trental. Vestnik Dermatologii i Venerologii 4: 51–52, 1985
Edwards MJ, Abney DL, Miller FN. Pentoxifylline inhibits interleukin-2-induced leukocyte-endothelial adherence and reduces systemic toxicity. Surgery 110: 199–204, 1991
Epstein JB, Stevenson-Moore P, Jackson S, Mohamed JH, Spinelli JJ. Prevention of oral mucositis in radiation therapy: a controlled study with benzydamine hydrochloride rinse. International Journal of Radiation Oncology, Biology, Physics 16: 1571–1575, 1989
Eriksson B, Johansson C, Aly A. Prostaglandin E2 for chronic leg ulcers. Lancet 1: 905, 1986
Ferretti GA, Ash RC, Brown AT, Parr MD, Romond EH, et al. Control of oral mucositis and candidiasis in marrow transplantation: a prospective, double-blind trial of chlorhexidine digluconate oral rinse. Bone Marrow Transplantation 3: 483–493, 1988
Ferretti GA, Raybould TP, Brown AT, Macdonald JS, Greenwood M, et al. Chlorhexidine prophylaxis for chemotherapy- and radiotherapy-induced stomatitis: a randomized double-blind trial. Oral Surgery, Oral Medicine, Oral Pathology 69: 331–338, 1990
Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. New England Journal of Medicine 318: 1414–1422, 1988
Garewal HS, Meyskens F. Retinoids and carotenoids in the prevention of oral cancer: a critical appraisal. Cancer Epidemiology, Biomarkers and Prevention 1: 155–159, 1992
Groopman JE, Molina JM, Scadden DT. Hematopoietic growth factors: biology and clinical applications. New England Journal of Medicine 321: 1449–1459, 1989
Han J, Thompson P, Beutler B. Dexamethasone and pentoxifyl-line inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. Journal of Experimental Medicine 172: 391–394, 1990
Howell SB, Wung WE, Taetle R, Hussain F, Romine JS. Modulation of 5-fluorouracil toxicity by allopurinol in man. Cancer 48: 1281–1289, 1981
Jansma J, Vissink A, Spijkervet FKL, Roodenburg JLN, Panders AK, et al. Protocol for the prevention and treatment of oral sequelae resulting from head and neck radiation therapy. Cancer 70: 2171–2180, 1992
Kim JH, Chu FCH, Lakshmi V, Houde R. Benzydamine HC1, a new agent for the treatment of radiation mucositis of the oropharynx. American Journal of Clinical Oncology 9: 132–134, 1986
Kuhrer I, Kuzmits R, Linkesch W, Ludwig H. Topical PGE2 enhances healing of chemotherapy-associated mucosal lesions. Lancet 1: 623, 1986
Lisciana R, Scorza-Barcellona P, Silvestrini B. Research on the topical activity of benzydamine. European Journal of Pharmacology 3: 157–162, 1968
Loprinzi CL, Cianflone SG, Dose AM, Etzell PS, Burnham NL, et al. A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis. Cancer 65: 1879–1882, 1990
Maciejewski B, Zajusz A, Pilecki B, Swiatnicka J, Skladowski K, et al. Acute mucositis in the stimulated oral mucosa of patients during radiotherapy for head and neck cancer. Radiotherapy and Oncology 22: 7–11, 1991
Mahood DJ, Dose AM, Loprinzi CL, Veeder MH, Athmann LM, et al. Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. Journal of Clinical Oncology 9: 449–452, 1991
McGaw WT, Belch A. Oral complications of acute leukemia: prophylactic impact of a chlorhexidine mouth rinse regimen. Oral Surgery, Oral Medicine, Oral Pathology 60: 275–280, 1985
Mills EED. The modifying effect of beta-carotene on radiation and chemotherapy induced oral mucositis. British Journal of Cancer 57: 416–417, 1988
Perry MC. Toxicity: ten years later. Seminars in Oncology 19: 453–457, 1992
Peterson DE. Pretreatment strategies for infection prevention in chemotherapy patients. National Cancer Institute Monograph 9: 61–71, 1990
Pettengell R, Gurney H, Radford JA, Deakin DP, James R, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin’s lymphoma: a randomized controlled trial. Blood 80: 1430–1436, 1992
Pfeiffer P, Madsen EL, Hansen O, May O. Effect of prophylactic sucralfate suspension on stomatitis induced by cancer chemotherapy: a randomized, double-blind cross-over study. Acta Oncologica 29: 171–173, 1990
Porteder H, Rausch E, Kment G, Watzek G, Matejka M, et al. Local prostaglandin E2 in patients with oral malignancies undergoing chemo- and radiotherapy. Journal of Cranio-Maxillary Facial Surgery 16: 371–374, 1988
Pourreau-Schneider N, Soudry M, Franquin JC, Zattara H, Martin PM, et al. Soft-laser therapy for iatrogenic mucositis in cancer patients receiving high-dose fluorouracil: a preliminary report. Journal of the National Cancer Institute 84: 358–359, 1992
Prada A, Chiesa F. Effects of benzydamine on the oral mucositis during antineoplastic radiotherapy and/or intra-arterial chemotherapy. International Journal of Tissue Reaction 9: 115–119, 1987
Schwartz PM, Dunigan JM, Marsh JC, Handschumacher RE. Allopurinol modification of the toxicity and antitumor activity of 5-fluorouracil. Cancer Research 40: 1885–1889, 1980
Schwartz PM, Handschumacher RE. Selective antagonism of 5-fluorouracil cytotoxicity by 4-hydroxypyrazolopyrimidine (allopurinol) in vitro. Cancer Research 39: 3095–3101, 1979
Segre G, Hammarstrom S. Aspects of the mechanisms of action of benzydamine. International Journal of Tissue Reactions 7: 187–193, 1985
Shenep JL, Kalwinsky DK, Hutson PR, George SL, Dodge RK, et al. Efficacy of oral sucralfate suspension in prevention and treatment of chemotherapy-induced mucositis. Journal of Pediatrics 113: 758–763, 1988
Solomon MA. Oral sucralfate suspension for mucositis. New England Journal of Medicine 315: 459–460, 1986
Sonis ST, Clairmont F, Lockhart PB, Connolly SF. Benzydamine HC1 in the management of chemotherapy-induced mucositis: I. Pilot Study. Journal of Oral Medicine 40: 61–71, 1985
Sonis S, Clark J. Prevention and management of oral mucositis induced by antineoplastic therapy. Oncology 5: 11–18, 1991
Spijkervet FKL, van Saene HKF, Panders AK, Vermey A, van Saene JJM, et al. Effect of chlorhexidine rinsing on the oropharyngeal ecology in patients with head and neck cancer who have irradiation mucositis. Oral Surgery, Oral Medicine, Oral Pathology 67: 154–61, 1989
Spijkervet FKL, van Saene HKF, van Saene JJM, Panders AK, Vermey A, et al. Effect of selective elimination of the oral flora on mucositis in irradiated head and neck cancer patients. Journal of Surgical Oncology 46: 167–173, 1991
Streiter RM, Remick DG, Ward PA, Spengler RN, Lynch III JP. Cellular and molecular regulation of tumor necrosis factor alpha production by pentoxifylline. Biochemical and Biophysical Research Communications 155: 1230–1236, 1988
Tarnawski A, Hollander D, Krause WJ, Zipser RD, Strachura J, et al. Does sucralfate affect the normal gastric mucosa? Histologic, ultrastructural, and functional assessment in the rat. Gastroenterology 90: 893–905, 1986
Tsavaris N, Caragiauris P, Kosmidis P. Reduction of oral toxicity of 5-fluorouracil by allopurinol mouthwashes. European Journal of Surgical Oncology 14: 405–406, 1988
Weisdorf DJ, Bostrom B, Raether D, Mattingly M, Walker P, et al. Oropharyngeal mucositis complicating bone marrow transplantation: prognostic factors and the effect of chlorhexidine mouth rinse. Bone Marrow Transplantation 4: 89–95, 1989
Weiss GR, Green S, Hannigan EV, Boutselis JG, Surwit EA, et al. A Phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trial. Gynecologic Oncology 37: 354–358, 1990
Weitgasser H. The use of pentoxifylline (Trental 400) in the treatment of leg ulcers: results of a double-blind trial. Pharmatherapeutica 3 (Suppl. 1): 143–151, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Verdi, C.J. Cancer Therapy and Oral Mucositis. Drug-Safety 9, 185–195 (1993). https://doi.org/10.2165/00002018-199309030-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-199309030-00004